Download PDF
Pharmacopsychiatry 2002; 35(1): 26-28
DOI: 10.1055/s-2002-19830
Case Report
© Georg Thieme Verlag Stuttgart · New York

Neuroleptic Malignant Syndrome in a Patient with Succinic Semialdehyde Dehydrogenase Deficiency

P.  Neu1 , S.  Seyfert2 , J.  Brockmöller3 , M.  Dettling4 , P.  Marx2
  • 1Department of Psychiatry, Freie Universität Berlin, Germany
  • 2Department of Neurology, Freie Universität Berlin, Germany
  • 3Department of Clinical Pharmacology, Charité, Humboldt Universität Berlin, Germany
  • 4Department of Psychiatry, Charité, Humboldt Universität Berlin, Germany
Further Information

Publication History

27. 4. 2000 · Revised 14. 12. 2000 / 9. 2. 2001

10. 3. 2001

Publication Date:
30 January 2002 (online)

Also available at
    Permissions and Reprints

A patient suffering from a rare enzyme deficiency developed a malignant neuroleptic syndrome after having been treated with one single dose of haloperidol. We investigated the patient's serum for all frequent polymorphisms in cytochrome P450 2D6, assuming him to be a poor neuroleptic metabolizer. We will also discuss other potential mechanisms inducing this disturbance and its differential diagnoses.

References

  • 1 Aicardi J. Diseases of the Nervous System in Childhood. 2nd edition. Cambridge; Mac Keith Press, University Press 1998
  • 2 Boyd R D. Neuroleptic malignant syndrome and mental retardation: review and analysis of 29 cases.  Am J Ment Retardation. 1993;  98 (3) 359
    PubMedGoogle Scholar
  • 3 Denborough M. Malignant hyperthermia.  Lancet. 1998;  352 1131-1136
    CrossrefPubMedGoogle Scholar
  • 4 Fink M. Neuroleptic Malignant Syndrome and Catatonia: One Entity or Two?.  Biol Psychiatry. 1996;  39 1-4
    CrossrefPubMedGoogle Scholar
  • 5 Fink M. Toxic Serotonin Syndrome or Neuroleptic Malignant Syndrome?.  Pharmacopsychiat. 1996;  29 159-161
    PubMedGoogle Scholar
  • 6 Gibson K M, Christensen E, Jakobs C. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency aciduria: case reports of 23 new patients.  Pediatrics. 1997;  99 567-574
    CrossrefPubMedGoogle Scholar
  • 7 Gibson K M, Hoffmann G F, Hodson A K, Boiglieri T, Jakobs C. 4-Hydroxybutyric acid and the clinical phenotype of succinic semialdehyde dehydrogenase deficiency, an inborn error of GABA metabolism.  Neuropediatrics. 1998;  29 (1) 14-22
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Guerra R J. Sympathoadrenal Hyperactivity and the Etiology of Neuroleptic Malignant Syndrome.  Am J Psychiatry. 1999;  156 169-180
    PubMedGoogle Scholar
  • 9 Hardman J G, Limbird L E, Molinoff P B, Ruddon R W, Gilnian A G. The Pharmacological basic of therapeutics. 9th edition. New York; MacGraw-Hill 1995: 1143
  • 10 Leonhard K. The Classification of Endogenous Psychoses, 5th ed. New York; Irvington 1979
  • 11 Levenson J L. Neuroleptic malignant syndrome.  Am J Psychiatry. 1985;  142 1137-1145
    CrossrefPubMedGoogle Scholar
  • 12 Mihara K, Suzuki A, Konto T, Yasui N, Furukori H, Nagashima U, Otani K, Kaneko S, Inoue Y. Effects of the CYP2D6*10 allele on the steady-state plasma concentrations of haloperidol in Japanese patients with schizophrenia.  Clin Pharmacol Ther. 1999;  65 (3) 291-294
    PubMedGoogle Scholar
  • 13 Nisijima K, Ishiguro T. Cerebrospinal fluid levels of monoamine metabolites and gamma-aminobutyric acid in neuroleptic malignant syndrome.  J Psychiat Res. 1995;  5/6 233-244
    PubMedGoogle Scholar
  • 14 Sachse C, Brockmöller J, Bauer S, Roots I. Cytochrome P450 2D6 Variants in a Caucasian Population: Allele Frequencies and Phenotypic Consequences.  Am J Hum Genet. 1997;  60 284-295
    PubMedGoogle Scholar
  • 15 Spina E, Ancione M, Di Rosa A E, Meduri M, Caputi A P. Polymorphic debrisoquine oxidation and acute neuroleptic-induced adverse effects.  Eur J Clin Pharmacol. 1992;  42 (3) 347-348
    PubMedGoogle Scholar

Dr. Peter Neu

Psychiatrische Poliklinik der FU Berlin

Eschenallee 3

14050 Berlin

Germany

Phone: + 49-30-8445-8673

Fax: + 49-30-8445-8388

Email: peter.neu@medizin.fu-berlin.de

      >